Mineralys Therapeutics Inc

MLYS appears in a Stage 2 recovery after a late-cycle capitulation; short-term EMAs have crossed above the 50 SMA signaling nascent bullish momentum, yet the 200 SMA remains overhead and acted as resistance in mid-September. A series of higher lows supports a base formation, giving a medium-term bullish bias against a bearish long-term trend. Execution is warranted on a pullback into the rising EMAs for continuation participation.

• ↑Cash on hand of $661M plus $500M credit facility extends runway to 2028.
• ↑Lorundrostat Phase II data show significant blood pressure drop and low hyperkalemia.
• ↓Q2 EPS of -$2.85 versus -$0.55 estimate indicates deteriorating earnings quality.